Business
Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology platform that covers this end-to-end modality range, supporting programs from in vitro ADME assays through in vivo PK and efficacy studies. Adventures in DMPK: From Small Molecules and PROTACs to Peptides and Antibodies, the latest session in the
About this update from Viva Biotech Holdings
[{"type":"text","content":"SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology platform that covers this end-to-end modality range, supporting programs from in vitro ADME assays through in vivo PK and efficacy studies. Adventures in DMPK: From Small Molecules and PROTACs to Peptides and Antibodies, the latest session in the Viva BioInsights webinar series, was presented by Dr. Justin Cui (Vice President of Pharmacology, Viva Biotech) and showcased these capabilities.","length":691,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Viva Biotech)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Viva Biotech)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":143,"url":"https://media.zenfs.com/en/prnewswire.com/1bdaf7b965393aced1e132cf142d2b89"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/t7dCRcB_pWclPGY7dRP0Yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI1MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1bdaf7b965393aced1e132cf142d2b89","width":400,"height":143}},"href":"https://mma.prnewswire.com/media/2784195/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Cui emphasized that small molecules, PROTACs, and peptides roughly share a common ADME/PK logic: physicochemical profiling and metabolic stability (e.g., microsomes, hepatocytes, S9/UGT, whole blood/plasma), permeability/transport (MDCK/Caco-2), DDI risk (CYP inhibition), and tailored exploratory assays, followed by multispecies PK with formulation screening. The differentiator is not the checklist, but the decision framework applied to large program volumes—using exposure metrics (e.g., AUC) and half-life to support early compound triage and deprioritization when profiles fall below internal thresholds.","length":615,"tagName":"p"},{"type":"text","content":"For peptide programs, Viva Biotech supports cross-species PK design (multiple routes such as SC/IV/IM) and comprehensive metabolite profiling (plasma, urine, bile, feces, tissues), with WinNonlin-based analysis used consistently across modalities. This consistent analytical framework enables comparison of peptide PK behavior along...